Akebia Broadens its Pipeline by Licensing J&J’s HIF-Based Portfolio
By Jawala Prasad
Pharma Deals Review: Vol 2017 Issue 3 (Table of Contents)
Published: 29 Mar-2017
DOI: 10.3833/pdr.v2017.i3.2233 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Akebia Therapeutics has partnered with Johnson and Johnson’s Janssen Pharmaceutica to explore a library of well-characterised molecules based on hypoxia-inducible factor (HIF) biology in a deal potentially worth more than US$230 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS